Molecular profiling of non-small cell lung cancer;Biologie moléculaire et prise en charge des patients atteints d'adénocarcinomes du poumon

Revue de Pneumologie Clinique

Volumn 70, Issue 1-2, 2014, Pages 47-62

  Gibault, L ^a   Cazes, A ^a,b   Narjoz, C ^c   Blons, H ^b,c,d  

^a Service de pathologie HÔpital européen Georges Pompidou Assistance publique HÔpitaux de Paris   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c HÔpital Européen Georges Pompidou   (France)

^d INSERM   (France)

Author keywords

Molecular biology; Non small cell lung cancer

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE INHIBITOR;

ALK GENE; BRAF GENE; GENE IDENTIFICATION; GENE MUTATION; GENE TARGETING; HUMAN; LUNG NON SMALL CELL CANCER; ONCOGENE; ONCOGENE K RAS; ONCOGENE NEU; PIK3CA GENE; RET GENE; REVIEW; ROS GENE; CARCINOMA, NON-SMALL-CELL LUNG; DECISION TREE; GENE EXPRESSION PROFILING; GENETICS; LUNG NEOPLASMS; MOLECULARLY TARGETED THERAPY; MUTATION;

CARCINOMA, NON-SMALL-CELL LUNG; DECISION TREES; GENE EXPRESSION PROFILING; HUMANS; LUNG NEOPLASMS; MOLECULAR TARGETED THERAPY; MUTATION;

EID: 84895920056     PISSN: 07618417     EISSN: 17762561     Source Type: Journal    
DOI: 10.1016/j.pneumo.2013.11.005     Document Type: Review

References (76)

1. Sharma S.V., Settleman J. Oncogene addiction: setting the stage for molecularly targeted cancer therapy. Genes Dev 2007, 21:3214-3231.
2. Pao W., Girard N. New driver mutations in non-small-cell lung cancer. Lancet Oncol 2011, 12:175-180.
3. Lievre A., Bachet J.B., Boige V., Cayre A., Le Corre D., et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 2008, 26:374-379.
4. Chapman P.B., Hauschild A., Robert C., Haanen J.B., Ascierto P., et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011, 364:2507-2516.
5. Lynch T.J., Bell D.W., Sordella R., Gurubhagavatula S., Okimoto R.A., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004, 350:2129-2139.
6. Sordella R., Bell D.W., Haber D.A., Settleman J. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 2004, 305:1163-1167.
7. Coate L.E., John T., Tsao M.S., Shepherd F.A. Molecular predictive and prognostic markers in non-small-cell lung cancer. Lancet Oncol 2009, 10:1001-1010.
8. Didelot A., Le Corre D., Luscan A., Cazes A., Pallier K., et al. Competitive allele specific TaqMan PCR for KRAS, BRAF and EGFR mutation detection in clinical formalin fixed paraffin embedded samples. Exp Mol Pathol 2012, 92:275-280.
9. Hirsch F.R., Varella-Garcia M., Bunn P.A., Di Maria M.V., Veve R., et al. Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol 2003, 21:3798-3807.
10. Calvo E., Baselga J. Ethnic differences in response to epidermal growth factor receptor tyrosine kinase inhibitors. J Clin Oncol 2006, 24:2158-2163.
11. Yatabe Y. EGFR mutations and the terminal respiratory unit. Cancer Metastasis Rev 2010, 29:23-36.
12. Riely G.J., Politi K.A., Miller V.A., Pao W. Update on epidermal growth factor receptor mutations in non-small cell lung cancer. Clin Cancer Res 2006, 12:7232-7241.
13. Li C., Fang R., Sun Y., Han X., Li F., et al. Spectrum of oncogenic driver mutations in lung adenocarcinomas from East Asian never smokers. PLoS One 2011, 6:e28204.
14. Wu J.Y., Yu C.J., Chang Y.C., Yang C.H., Shih J.Y., et al. Effectiveness of tyrosine kinase inhibitors on "uncommon" epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer. Clin Cancer Res 2011, 17:3812-3821.
15. Greulich H., Chen T.H., Feng W., Janne P.A., Alvarez J.V., et al. Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants. PLoS Med 2005, 2:e313.
16. Kancha R.K., von Bubnoff N., Peschel C., Duyster J. Functional analysis of epidermal growth factor receptor (EGFR) mutations and potential implications for EGFR targeted therapy. Clin Cancer Res 2009, 15:460-467.
17. Forbes S., Clements J., Dawson E., Bamford S., Webb T., et al. Cosmic 2005. Br J Cancer 2006, 94:318-322.
18. Cortes-Funes H., Gomez C., Rosell R., Valero P., Garcia-Giron C., et al. Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small-cell lung cancer patients. Ann Oncol 2005, 16:1081-1086.
19. Han S.W., Kim T.Y., Hwang P.G., Jeong S., Kim J., et al. Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol 2005, 23:2493-2501.
20. Mitsudomi T., Kosaka T., Endoh H., Horio Y., Hida T., et al. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol 2005, 23:2513-2520.
21. Taron M., Ichinose Y., Rosell R., Mok T., Massuti B., et al. Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas. Clin Cancer Res 2005, 11:5878-5885.
22. Mok T.S., Wu Y.L., Thongprasert S., Yang C.H., Chu D.T., et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009, 361:947-957.
23. Mitsudomi T., Morita S., Yatabe Y., Negoro S., Okamoto I., et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3trial. Lancet Oncol 2010, 11:121-128.
24. Ji H., Li D., Chen L., Shimamura T., Kobayashi S., et al. The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies. Cancer Cell 2006, 9:485-495.
25. Carey K.D., Garton A.J., Romero M.S., Kahler J., Thomson S., et al. Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib. Cancer Res 2006, 66:8163-8171.
26. Jackman D.M., Yeap B.Y., Sequist L.V., Lindeman N., Holmes A.J., et al. Exon 19deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib. Clin Cancer Res 2006, 12:3908-3914.
27. Gandhi J., Zhang J., Xie Y., Soh J., Shigematsu H., et al. Alterations in genes of the EGFR signaling pathway and their relationship to EGFR tyrosine kinase inhibitor sensitivity in lung cancer cell lines. PLoS One 2009, 4:e4576.
28. De Pas T., Toffalorio F., Manzotti M., Fumagalli C., Spitaleri G., et al. Activity of epidermal growth factor receptor-tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring rare epidermal growth factor receptor mutations. J Thorac Oncol 2011, 6:1895-1901.
29. Kobayashi S., Boggon T.J., Dayaram T., Janne P.A., Kocher O., et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 2005, 352:786-792.
30. Sasaki H., Endo K., Takada M., Kawahara M., Kitahara N., et al. EGFR exon 20insertion mutation in Japanese lung cancer. Lung Cancer 2007, 58:324-328.
31. Wu J.Y., Wu S.G., Yang C.H., Gow C.H., Chang Y.L., et al. Lung cancer with epidermal growth factor receptor exon 20mutations is associated with poor gefitinib treatment response. Clin Cancer Res 2008, 14:4877-4882.
32. Suda K., Onozato R., Yatabe Y., Mitsudomi T. EGFR T790M mutation: a double role in lung cancer cell survival?. J Thorac Oncol 2009, 4:1-4.
33. Yun C.H., Mengwasser K.E., Toms A.V., Woo M.S., Greulich H., et al. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci U S A 2008, 105:2070-2075.
34. Pao W., Miller V.A., Politi K.A., Riely G.J., Somwar R., et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005, 2:e73.
35. Oxnard G.R., Arcila M.E., Sima C.S., Riely G.J., Chmielecki J., et al. Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation. Clin Cancer Res 2011, 17:1616-1622.
36. Su K.Y., Chen H.Y., Li K.C., Kuo M.L., Yang J.C., et al. Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer. J Clin Oncol 2012, 30:433-440.
37. Fujita Y., Suda K., Kimura H., Matsumoto K., Arao T., et al. Highly sensitive detection of EGFR T790M mutation using colony hybridization predicts favorable prognosis of patients with lung cancer harboring activating EGFR mutation. J Thorac Oncol 2012, 7:1640-1644.
38. Zhou W., Ercan D., Chen L., Yun C.H., Li D., et al. Novel mutant-selective EGFR kinase inhibitors against EGFR T790M. Nature 2009, 462:1070-1074.
39. Yu H.A., Arcila M.E., Rekhtman N., Sima C.S., Zakowski M.F., et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155patients with EGFR-mutant lung cancers. Clin Cancer Res 2013, 19:2240-2247.
40. Taniguchi K., Uchida J., Nishino K., Kumagai T., Okuyama T., et al. Quantitative detection of EGFR mutations in circulating tumor DNA derived from lung adenocarcinomas. Clin Cancer Res 2011, 17:7808-7815.
41. Didelot A., Kotsopoulos S.K., Lupo A., Pekin D., Li X., et al. Multiplex picoliter-droplet digital PCR for quantitative assessment of DNA integrity in clinical samples. Clin Chem 2013, 59:815-823.
42. Kim Y.T., Seong Y.W., Jung Y.J., Jeon Y.K., Park I.K., et al. The presence of mutations in epidermal growth factor receptor gene is not a prognostic factor for long-term outcome after surgical resection of non-small-cell lung cancer. J Thorac Oncol 2013, 8:171-178.
43. Gerlinger M., Rowan A.J., Horswell S., Larkin J., Endesfelder D., et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012, 366:883-892.
44. Mattsson J.S., Imgenberg-Kreuz J., Edlund K., Botling J., Micke P. Consistent mutation status within histologically heterogeneous lung cancer lesions. Histopathology 2011, 61:744-748.
45. Yatabe Y., Matsuo K., Mitsudomi T. Heterogeneous distribution of EGFR mutations is extremely rare in lung adenocarcinoma. J Clin Oncol 2011, 29:2972-2977.
46. Sakurada A., Lara-Guerra H., Liu N., Shepherd F.A., Tsao M.S. Tissue heterogeneity of EGFR mutation in lung adenocarcinoma. J Thorac Oncol 2008, 3:527-529.
47. Shimizu K., Yukawa T., Hirami Y., Okita R., Saisho S., et al. Heterogeneity of the EGFR mutation status between the primary tumor and metastatic lymph node and the sensitivity to EGFR tyrosine kinase inhibitor in non-small cell lung cancer. Target Oncol 2012, 8:237-242.
48. Taniguchi K., Okami J., Kodama K., Higashiyama M., Kato K. Intratumor heterogeneity of epidermal growth factor receptor mutations in lung cancer and its correlation to the response to gefitinib. Cancer Sci 2008, 99:929-935.
49. Grob T.J., Hoenig T., Clauditz T.S., Atanackovic D., Koenig A.M., et al. Frequent intratumoral heterogeneity of EGFR gene copy gain in non-small cell lung cancer. Lung Cancer 2012, 79:221-227.
50. Yatabe Y., Takahashi T., Mitsudomi T. Epidermal growth factor receptor gene amplification is acquired in association with tumor progression of EGFR-mutated lung cancer. Cancer Res 2008, 68:2106-2111.
51. Shigematsu H., Takahashi T., Nomura M., Majmudar K., Suzuki M., et al. Somatic mutations of the HER2kinase domain in lung adenocarcinomas. Cancer Res 2005, 65:1642-1646.
52. Mazieres J., Peters S., Lepage B., Cortot A.B., Barlesi F., et al. Lung cancer that harbors an HER2mutation: epidemiologic characteristics and therapeutic perspectives. J Clin Oncol 2013, 31:1997-2003.
53. Bean J., Brennan C., Shih J.Y., Riely G., Viale A., et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci U S A 2007, 104:20932-20937.
54. Ruppert A.M., Beau-Faller M., Belmont L., Lavole A., Gounant V., et al. A simple view on lung cancer biology: the MET pathway. Rev Mal Respir 2011, 28:1241-1249.
55. Riely G.J., Marks J., Pao W. KRAS mutations in non-small cell lung cancer. Proc Am Thorac Soc 2009, 6:201-205.
56. Roberts P.J., Stinchcombe T.E. KRAS mutation: should we test for it, and does it matter?. J Clin Oncol 2013, 31:1112-1120.
57. Fiala O., Pesek M., Finek J., Benesova L., Belsanova B., et al. The dominant role of G12C over other KRAS mutation types in the negative prediction of efficacy of epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Cancer Genet 2013, 206:26-31.
58. Paik P.K., Arcila M.E., Fara M., Sima C.S., Miller V.A., et al. Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations. J Clin Oncol 2011, 29:2046-2050.
59. Pallier K., Houllier A.M., Le Corre D., Cazes A., Laurent-Puig P., et al. No somatic genetic change in the paxillin gene in non-small-cell lung cancer. Mol Carcinog 2009, 48:581-585.
60. Do H., Solomon B., Mitchell P.L., Fox S.B., Dobrovic A. Detection of the transforming AKT1mutation E17K in non-small cell lung cancer by high resolution melting. BMC Res Notes 2008, 1:14.
61. Shackelford D.B., Abt E., Gerken L., Vasquez D.S., Seki A., et al. LKB1inactivation dictates therapeutic response of non-small cell lung cancer to the metabolism drug phenformin. Cancer Cell 2013, 23:143-158.
62. Davies K.D., Doebele R.C. Molecular pathways: ROS1fusion proteins in cancer. Clin Cancer Res 2013, 19:4040-4050.
63. Bergethon K., Shaw A.T., Ou S.H., Katayama R., Lovly C.M., et al. ROS1rearrangements define a unique molecular class of lung cancers. J Clin Oncol 2012, 30:863-870.
64. Wang R., Hu H., Pan Y., Li Y., Ye T., et al. RET fusions define a unique molecular and clinicopathologic subtype of non-small-cell lung cancer. J Clin Oncol 2012, 30:4352-4360.
65. Travis W.D., Brambilla E., Noguchi M., Nicholson A.G., Geisinger K.R., et al. International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 2011, 6:244-285.
66. Yoshida A., Tsuta K., Watanabe S., Sekine I., Fukayama M., et al. Frequent ALK rearrangement and TTF-1/p63co-expression in lung adenocarcinoma with signet-ring cell component. Lung Cancer 2011, 72:309-315.
67. Antoine M., Poulot V., Colombat M., Fleury J., Lacave R., et al. Pretreatment molecular biology analysis on small size biopsies. Ann Pathol 2010, 30:67-72.
68. Lindeman N.I., Cagle P.T., Beasley M.B., Chitale D.A., Dacic S., et al. Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists. International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J Mol Diagn 2013, 15:415-453.
69. Rekhtman N., Paik P.K., Arcila M.E., Tafe L.J., Oxnard G.R., et al. Clarifying the spectrum of driver oncogene mutations in biomarker-verified squamous carcinoma of lung: lack of EGFR/KRAS and presence of PIK3CA/AKT1mutations. Clin Cancer Res 2012, 18:1167-1170.
70. Hofman V., Ilie M., Gavric-Tanga V., Lespinet V., Mari M., et al. Role of the surgical pathology laboratory in the pre-analytical approach of molecular biology techniques. Ann Pathol 2010, 30:85-93.
71. Srinivasan M., Sedmak D., Jewell S. Effect of fixatives and tissue processing on the content and integrity of nucleic acids. Am J Pathol 2002, 161:1961-1970.
72. Sasaki T., Rodig S.J., Chirieac L.R., Janne P.A. The biology and treatment of EML4-ALK non-small cell lung cancer. Eur J Cancer 2010, 46:1773-1780.
73. Camidge D.R., Kono S.A., Flacco A., Tan A.C., Doebele R.C., et al. Optimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment. Clin Cancer Res 2010, 16:5581-5590.
74. Just P.A., Cazes A., Audebourg A., Cessot A., Pallier K., et al. Histologic subtypes, immunohistochemistry, FISH or molecular screening for the accurate diagnosis of ALK-rearrangement in lung cancer: a comprehensive study of Caucasian non-smokers. Lung Cancer 2012, 76:309-315.
75. McLeer-Florin A., Moro-Sibilot D., Melis A., Salameire D., Lefebvre C., et al. Dual IHC and FISH testing for ALK gene rearrangement in lung adenocarcinomas in a routine practice: a French study. J Thorac Oncol 2012, 7:348-354.
76. Rimkunas V.M., Crosby K.E., Li D., Hu Y., Kelly M.E., et al. Analysis of receptor tyrosine kinase ROS1-positive tumors in non-small cell lung cancer: identification of a FIG-ROS1fusion. Clin Cancer Res 2012, 18:4449-4450.